Evidence of functional gastric inhibitory polypeptide (GIP) receptors in human insulinoma. Binding of synthetic human GIP 1-31 and activation of adenylate cyclase.
Specific gastric inhibitory polypeptide (GIP) receptors were characterized in human benign insulinoma plasma membranes employing [mono-[125I]iodo-Tyr10]-GIP (125I-GIP) as the radioligand. GIP 1-42 inhibited 125I-GIP binding with an IC50 value of 10(-9) M. Scatchard analysis showed two classes of binding sites: a high-affinity site (Kd = 2.23 x 10(-10) M; Bmax = 24 fmol/mg protein) and a low-affinity site (Kd = 8.39 x 10(-9) M; Bmax = 118 fmol/mg protein). A synthetic replicate of human GIP 1-31 inhibited 125I-GIP binding with an IC50 value of 10(-8) M. The GIP binding sites of human insulinoma were coupled to adenylate cyclase stimulation. GIP 1-31 regulated the adenylate cyclase activity to the same extent as GIP 1-42. The concentrations of GIP required for maximal activity ranged from 10(-9) to 10(-8) M for either GIP 1-42 or GIP 1-31. The existence of functional GIP receptors in human insulinoma substantiates our recent reports demonstrating the presence of GIP binding sites in transplantable hamster insulinoma and indicates that GIP could exert a direct control of the beta-cell function in humans through a purely endocrine pathway.
Maletti
M
M
Fondation de Recherche en Hormonologie, Fresnes, France.
Altman
J J
JJ
Hoa
D H
DH
Carlquist
M
M
Rosselin
G
G
D007516:Adenoma, Islet Cell / Q000378:metabolism*; D000328:Adult; D002462:Cell Membrane / Q000378:metabolism; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism*; D006801:Humans; D007340:Insulinoma / Q000378:metabolism* / Q000473:pathology; D007700:Kinetics; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D011964:Receptors, Gastrointestinal Hormone / Q000378:metabolism*
D011964:Receptors, Gastrointestinal Hormone; D005749:Gastric Inhibitory Polypeptide; C041086:gastric inhibitory polypeptide receptor